JP2017525777A - 可溶性エポキシドヒドロラーゼ阻害剤及びこれらの使用 - Google Patents

可溶性エポキシドヒドロラーゼ阻害剤及びこれらの使用 Download PDF

Info

Publication number
JP2017525777A
JP2017525777A JP2017530962A JP2017530962A JP2017525777A JP 2017525777 A JP2017525777 A JP 2017525777A JP 2017530962 A JP2017530962 A JP 2017530962A JP 2017530962 A JP2017530962 A JP 2017530962A JP 2017525777 A JP2017525777 A JP 2017525777A
Authority
JP
Japan
Prior art keywords
alkyl
subject
compound according
compound
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017530962A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017525777A5 (enExample
Inventor
ジャン，イン
キーフェ，アンソニー，ディー．
ドゥメリン，クリストフ
Original Assignee
エックス−ケム，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エックス−ケム，インコーポレーテッド filed Critical エックス−ケム，インコーポレーテッド
Publication of JP2017525777A publication Critical patent/JP2017525777A/ja
Publication of JP2017525777A5 publication Critical patent/JP2017525777A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2017530962A 2014-08-28 2015-08-26 可溶性エポキシドヒドロラーゼ阻害剤及びこれらの使用 Pending JP2017525777A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462043275P 2014-08-28 2014-08-28
US62/043,275 2014-08-28
PCT/US2015/046878 WO2016033150A1 (en) 2014-08-28 2015-08-26 Soluble epoxide hydrolase inhibitors and uses thereof

Publications (2)

Publication Number Publication Date
JP2017525777A true JP2017525777A (ja) 2017-09-07
JP2017525777A5 JP2017525777A5 (enExample) 2018-09-27

Family

ID=55400481

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017530962A Pending JP2017525777A (ja) 2014-08-28 2015-08-26 可溶性エポキシドヒドロラーゼ阻害剤及びこれらの使用

Country Status (8)

Country Link
US (2) US10081616B2 (enExample)
EP (1) EP3186228A4 (enExample)
JP (1) JP2017525777A (enExample)
CN (2) CN107074771B (enExample)
AU (2) AU2015306643B2 (enExample)
CA (1) CA2958881A1 (enExample)
MA (1) MA40538A (enExample)
WO (1) WO2016033150A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017525777A (ja) * 2014-08-28 2017-09-07 エックス−ケム，インコーポレーテッド 可溶性エポキシドヒドロラーゼ阻害剤及びこれらの使用
EP3600266B1 (en) * 2017-03-30 2022-07-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Pharmaceutical compositions for use in the treatment of cardiovascular calcification
US20230071934A1 (en) * 2019-12-18 2023-03-09 Intra-Cellular Therapies, Inc. Novel uses
WO2024105225A1 (en) 2022-11-18 2024-05-23 Universitat De Barcelona Synergistic combinations of a sigma receptor 1 (s1r) antagonist and a soluble epoxide hydrolase inhibitor (sehi) and their use in the treatment of pain

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3245950A1 (de) * 1981-12-24 1983-07-07 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Verfahren zur herstellung substituierter pyridine
JP2006504731A (ja) * 2002-10-04 2006-02-09 アボット・ラボラトリーズ 血管新生を阻害する方法
WO2008152099A2 (en) * 2007-06-13 2008-12-18 Bayer Schering Pharma Aktiengesellschaft Aryl/hetarylamides as modulators of the ep2 receptor
JP2009528992A (ja) * 2006-02-16 2009-08-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 可溶性エポキシド加水分解酵素阻害剤として有益な置換ピリジンアミン化合物
JP2010500977A (ja) * 2006-08-09 2010-01-14 スミスクライン ビーチャム コーポレーション オピオイド受容体のアンタゴニストまたはインバースアゴニストである新規化合物
EP2149551A1 (de) * 2008-07-30 2010-02-03 Bayer Schering Pharma AG N-(Indol-3-ylalkyl)-(hetero)arylamidderivate als Modulatoren des EP2-Rezeptors
EP2149552A1 (de) * 2008-07-30 2010-02-03 Bayer Schering Pharma AG 5,6 substituierte Benzamid-Derivate als Modulatoren des EP2-Rezeptors
JP2010513458A (ja) * 2006-12-19 2010-04-30 ファイザー・プロダクツ・インク Ｈ−ｐｇｄｓの阻害剤としてのニコチンアミド誘導体、およびプロスタグランジンｄ２の仲介による疾患を治療するためのその使用
JP2011524894A (ja) * 2008-06-18 2011-09-08 ファイザー・リミテッド ニコチンアミド誘導体
JP2011524893A (ja) * 2008-06-18 2011-09-08 ファイザー・リミテッド ニコチンアミド誘導体
WO2013057253A1 (en) * 2011-10-21 2013-04-25 F. Hoffmann-La Roche Ag Pyrimidin-4-one derivatives and their use in the treatment, amelioration or prevention of a viral disease
WO2013064467A1 (en) * 2011-11-01 2013-05-10 F. Hoffmann-La Roche Ag Azetidine compounds, compositions and their use as inhibitors of soluble epoxide hydrolase

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR037233A1 (es) * 2001-09-07 2004-11-03 Euro Celtique Sa Piridinas aril sustituidas, composiciones farmaceuticas y el uso de dichos compuestos para la elaboracion de un medicamento
CA2643859A1 (en) 2006-03-10 2007-09-20 Boehringer Ingelheim International Gmbh Soluble epoxide hydrolase inhibitors and methods of using same
WO2009151800A1 (en) * 2008-05-07 2009-12-17 Merck & Co., Inc. Soluble epoxide hydrolase inhibitors, compositions containing such compounds and methods of treatment
US20100113512A1 (en) * 2008-10-30 2010-05-06 Diane Michele Ignar Method of treatment using novel antagonists or inverse agonists at opioid receptors
WO2010080183A1 (en) 2009-01-08 2010-07-15 The Trustees Of Columbia University In The City Of New York Potent non-urea inhibitors of soluble epoxide hydrolase
WO2011091410A1 (en) * 2010-01-25 2011-07-28 Glaxos Smithkline Llc Trpv4 antagonists
US20130102600A1 (en) * 2011-10-21 2013-04-25 F. Hoffmann-La Roche Ltd Heteroaryl hydroxamic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
WO2013112751A1 (en) * 2012-01-25 2013-08-01 The Trustees Of Columbia University In The City Of New York Potent non-urea inhibitors of soluble epoxide hydrolase
KR20150085045A (ko) * 2012-11-16 2015-07-22 메르크 파텐트 게엠베하 3-아미노시클로펜탄 카르복사미드 유도체
CN104016914B (zh) * 2014-05-27 2016-03-30 苏州科技学院 一种酰胺化合物的制备方法
JP2017525777A (ja) * 2014-08-28 2017-09-07 エックス−ケム，インコーポレーテッド 可溶性エポキシドヒドロラーゼ阻害剤及びこれらの使用

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3245950A1 (de) * 1981-12-24 1983-07-07 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Verfahren zur herstellung substituierter pyridine
JP2006504731A (ja) * 2002-10-04 2006-02-09 アボット・ラボラトリーズ 血管新生を阻害する方法
JP2009528992A (ja) * 2006-02-16 2009-08-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 可溶性エポキシド加水分解酵素阻害剤として有益な置換ピリジンアミン化合物
JP2010500977A (ja) * 2006-08-09 2010-01-14 スミスクライン ビーチャム コーポレーション オピオイド受容体のアンタゴニストまたはインバースアゴニストである新規化合物
JP2010513458A (ja) * 2006-12-19 2010-04-30 ファイザー・プロダクツ・インク Ｈ−ｐｇｄｓの阻害剤としてのニコチンアミド誘導体、およびプロスタグランジンｄ２の仲介による疾患を治療するためのその使用
WO2008152099A2 (en) * 2007-06-13 2008-12-18 Bayer Schering Pharma Aktiengesellschaft Aryl/hetarylamides as modulators of the ep2 receptor
JP2011524894A (ja) * 2008-06-18 2011-09-08 ファイザー・リミテッド ニコチンアミド誘導体
JP2011524893A (ja) * 2008-06-18 2011-09-08 ファイザー・リミテッド ニコチンアミド誘導体
EP2149551A1 (de) * 2008-07-30 2010-02-03 Bayer Schering Pharma AG N-(Indol-3-ylalkyl)-(hetero)arylamidderivate als Modulatoren des EP2-Rezeptors
EP2149552A1 (de) * 2008-07-30 2010-02-03 Bayer Schering Pharma AG 5,6 substituierte Benzamid-Derivate als Modulatoren des EP2-Rezeptors
WO2013057253A1 (en) * 2011-10-21 2013-04-25 F. Hoffmann-La Roche Ag Pyrimidin-4-one derivatives and their use in the treatment, amelioration or prevention of a viral disease
WO2013064467A1 (en) * 2011-11-01 2013-05-10 F. Hoffmann-La Roche Ag Azetidine compounds, compositions and their use as inhibitors of soluble epoxide hydrolase

Also Published As

Publication number Publication date
AU2015306643A1 (en) 2017-03-16
CN111454246A (zh) 2020-07-28
EP3186228A1 (en) 2017-07-05
AU2020207828A1 (en) 2020-08-13
CN107074771A (zh) 2017-08-18
US20180362499A1 (en) 2018-12-20
US10081616B2 (en) 2018-09-25
EP3186228A4 (en) 2018-04-18
AU2015306643B2 (en) 2020-05-07
WO2016033150A1 (en) 2016-03-03
CN107074771B (zh) 2020-03-20
US20170240526A1 (en) 2017-08-24
MA40538A (fr) 2021-04-07
CA2958881A1 (en) 2016-03-03

Similar Documents

Publication Publication Date Title
US10487087B2 (en) Positive allosteric modulators of the GLP-1 receptor
JP7469522B2 (ja) ベンゾチアゾール類誘導体及びその使用
AU2020207828A1 (en) Soluble epoxide hydrolase inhibitors and uses thereof
EP3703680B1 (en) Antagonists of the muscarinic acetylcholine receptor m4
WO2013138753A1 (en) Prodrugs of riluzole and their method of use
EP3746421B1 (en) Antagonists of the muscarinic acetylcholine receptor m4
US9862678B2 (en) 3,4-diaminobenzenesulfonamide derivatives for inhibiting cell death
EP3697781B1 (en) Antagonists of the muscarinic acetylcholine receptor m4
WO2019126559A1 (en) Antagonists of the muscarinic acetylcholine receptor m4
US20200369666A1 (en) Antagonists of the muscarinic acetylcholine receptor m4
CA3099791A1 (en) Compositions and methods for reducing tactile dysfunction, anxiety, and social impairment
JP2019514899A (ja) 共有結合型ｂｔｋ阻害剤及びその使用
WO2019079609A1 (en) SEH / PDE4 DOUBLE INHIBITORS AVAILABLE ORAL
EP2185525B1 (fr) Dérivés de pyrazole 3,5-carboxylates, leur préparation et leur application en thérapeutique
WO2019046465A2 (en) THERAPEUTIC INDOLES
WO2010109115A1 (fr) Composés anticancéreux, leur préparation et leur application en thérapeutique
AU2007260298A1 (en) Pyrrolidine compounds as renin inhibitors
JP2025526368A (ja) Ｉｒａｋ３のリガンド指向性分解分子としての置換ピラゾリル－ピリジニル化合物
KR100723539B1 (ko) 데포르밀라제 저해제, 이의 제조방법, 및 이를 포함하는조성물
WO2022243651A1 (fr) Nouveaux derives azaindole en tant qu'agents anticancereux
EA045146B1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
JP2006347940A (ja) βアミロイド生成抑制剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180814

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180814

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190425

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190514

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190726

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191008

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191029

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200430

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200612

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200804